Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model

• Published in: Endocrine-related cancer Vol. 17; no. 1; pp. 169 - 177
• Main Authors: Luconi, Michaela, Mangoni, Monica, Gelmini, Stefania, Poli, Giada, Nesi, Gabriella, Francalanci, Michela, Pratesi, Nicola, Cantini, Giulia, Lombardi, Adriana, Pepi, Monica, Ercolino, Tonino, Serio, Mario, Orlando, Claudio, Mannelli, Massimo
• Format: Journal Article
• Language: English
• Published: England Society for Endocrinology 01.03.2010; BioScientifica
• Subjects: Adrenal Cortex Neoplasms - drug therapy; Adrenal Cortex Neoplasms - genetics; Adrenal Cortex Neoplasms - pathology; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Carcinoma - drug therapy; Carcinoma - genetics; Carcinoma - pathology; Cell Line, Tumor; Cell Proliferation - drug effects; Female; Gene Expression Regulation, Neoplastic - drug effects; Humans; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Mice; Mice, Nude; Regular papers; Thiazolidinediones - pharmacology; Thiazolidinediones - therapeutic use; Tumor Burden - drug effects; Xenograft Model Antitumor Assays
• ISSN: 1351-0088; 1479-6821
• DOI: 10.1677/ERC-09-0170

Adrenocortical carcinoma (ACC) is a rare aggressive tumor with a poor prognosis. The lack of a specific and effective medical treatment is due to the poor knowledge of the mechanisms underlying tumor growth. Research on potential drugs able to specifically interfere with tumor proliferation is essential to develop more efficacious therapies. We evaluated for the first time the in vivo effect of rosiglitazone (RGZ), an anti-diabetic drug with in vitro anti-tumor properties, on ACC proliferation in a xenograft model obtained by s.c. injection of human ACC H295R cells in athymic mice. When the tumor size reached 5 mm, animals were allocated to 5 mg/kg RGZ- or water-treated groups. Tumor volume was measured twice a week. A significant reduction of tumor growth in RGZ versus control (control) group was observed and was already maximal following 17 day treatment (1−T/C=75.4% (43.7–93.8%)). After 31 days of treatment, mice were killed and tumor analyzed. Tumor histological evaluation revealed characteristics of invasiveness, richness in small vessels and mitotic figures in control group, while RGZ group tumors presented non infiltrating borders, few vessels, and many apoptotic bodies. Tumor immunohistochemistry showed that Ki-67 was reduced in RGZ versus control group. Quantitative real-time RT-PCR demonstrated a significant reduction in the expression of angiogenic (VEGF), vascular (CD31), proliferation (BMI-1), and anti-apoptotic (Bcl-2) genes in RGZ versus control group tumors. The same inhibitory effects were confirmed in in vitro RGZ-treated H295R. Our findings support and expand the role of RGZ in controlling ACC proliferation and angiogenesis in vivo and in vitro.